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I try to get confirmation of insurance coverage for the use of 
4 mg of zoledronic acid every 6 months for postmenopausal 
patients. Only few patients are willing to pay out of their own 
pocket, and in such patients, too, zoledronic acid is the drug of 
choice. Generic zoledronic acid is available in Europe; thus 
the pharmaceutical industry will likely have a low incentive to 
register the adjuvant use. Mechanisms that are independent 
of pharmaceutical companies are urgently needed to update 
the label of old drugs.
Gnant: Adjuvant bisphosphonates are effective in reducing 
bone metastases (and probably non-bone metastases to some 
extent) in patients with ‘low-estrogen’ environments. Given 
the lack of licensed drugs in this indication, I am discussing 
preventive use of zoledronic acid with premenopausal pa-
tients on ovarian function suppression and tamoxifen (based 
on ABCSG-12), and zoledronic acid or clodronate with 
clearly postmenopausal patients.
Leo: Robert Coleman introduced a meta-analysis that in-
volved 36 trials of adjuvant bisphosphonates in breast cancer 
with 17,791 pre- and postmenopausal women. This analysis 
demonstrated a significant survival benefit for postmenopau-
sal women who received bisphosphonates in an adjuvant set-
ting. The type and dosage of the used bisphosphonate did not 
matter. This meta-analysis clearly sheds light onto the contro-
versial discussion whether or not bisphosphonates should 
have a role as a standard adjuvant treatment. And with an ab-
solute breast cancer mortality risk reduction of 3.1% this 
treatment can compare well to other adjuvant substances 
 introduced over the past years. Still, the data have to be han-
dled with caution since a huge part of the analysis is based on 
the AZURE patients who define the hypothesis-generating 
population. Since bisphosphonates are already well used in 
preventing bone loss associated with aromatase inhibitor use 
in postmenopausal women they might already prevent recur-
Question 1: Which Patients Should  
Be Offered Chemoprevention?
Leo: Dr. Cuzick presented results from the phase III IBIS-
II trial that evaluated whether anastrozole prevents the devel-
opment of breast cancer in women at increased risk. Although 
anastrozole was demonstrated to significantly lower the inci-
dence of all breast cancers and seemed to be well tolerated, 
the side effects still cannot be neglected. Especially musculo-
skeletal events and a slight increase in fracture rate are im-
portant considerations when recommending such a chemo-
preventive therapy in otherwise healthy women. Certainly, 
anastrozole – in addition to tamoxifen and exemestane – 
might be an option but should still be individually discussed 
with the woman at risk. 
Gnant: Chemoprevention is always an individualized 
 balancing for risks and benefits. Based on the IBIS-II results, 
I am discussing preventive anastrozole with high-risk women 
based on family history, in-situ lesions, and breast density.
Harbeck: Women fulfilling the IBIS-II inclusion criteria 
need to be informed about the possibility of chemoprevention 
with an aromatase inhibitor (AI). Yet, the individual decision 
will certainly need to balance risk for breast cancer vs. side 
 effects and quality of life. 
Question 2: How Do You Prescribe Adjuvant Bis-
phosphonates? (Which Patients? Which Substance? 
Which Dosage?) 
Aebi: Given the current state of reimbursement, the adju-
vant use of bisphosphonates is often not feasible. For post-
menopausal patients (iatrogenic and natural menopause) I try 
to find osteoporosis to justify the use of zoledronic acid, and 
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rences in that patient population. We will have to see how 
guideline panels assess these new data and whether they will 
be implemented in state-of-the-art recommendations.     
Harbeck: The EBCTCG meta-analysis showed that adju-
vant bisphosphonates are effective primarily in postmenopau-
sal patients. The effect on reduction of bone metastasis and 
mortality was independent of hormone receptor status. It also 
did not differ according to type and regimen of bisphospho-
nates. We now offer adjuvant bisphosphonates to all post-
menopausal patients and to premenopausal patients who are 
treated by GnRH + tamoxifen according to the ABCSG-12 
results. Our preferred regimen is zoledronic acid every 
6 months for 3 years. 
Question 3: How Do You View Local Surgery  
in Case of Metastasized Disease?
Aebi: The question is still unresolved, but the 2 trials re-
ported from India (Badwe) and Turkey (Soran) do not sup-
port local surgery for stage IV disease. The statistical analysis 
of both trials does not allow conclusions with regard to spe-
cial populations such as patients with oligometastatic disease 
in whom the primary and all detectable metastatic disease 
could be removed by surgery. Thus, surgery of the primary 
for patients with stage IV disease is indicated for local pallia-
tion but should be considered experimental for all other 
indications.
Gnant: The idea of eliminating stem cells from the general-
ized disease is fascinating – however the reported trials from 
Tata Memorial in Mumbay and Turkey, respectively, have 
been negative. I am not convinced that the methodology of 
these trials can be viewed as sufficient to settle the issue. 
 Further trials are ongoing and should be supported.
Harbeck: Systemic therapy is the standard in primary 
 metastatic disease. In patients with good response, I still con-
sider resection of the primary tumor as an option if R0 resec-
tion can be achieved. We do not have evidence that this will 
increase survival but individual patients may opt for it for 
 psychological or other reasons. I do not think that the 2 trials 
presented at SABCS represent our therapeutic reality – we 
need more data to definitely rule out this option. Neverthe-
less, the investigators need to be congratulated for completing 
recruitment.
Leo: At the SABCS 2013, 2 prospective trials regarding 
this topic were discussed (Badwe et al., Soran et al.). Both 
studies did not show a survival benefit for patients that were 
metastasized at first presentation and who received loco-
regional treatment either before or after systemic therapy. 
These 2 important trials suggest that locoregional treatment 
should not be offered to stage IV patients in routine clinical 
practice but should be reserved for palliation for fungating or 
bleeding primary breast tumors. 
Question 4: Should We Forego Radiation after 
Breast Conserving Surgery in Elderly Patients?  
Is There a New Standard?
Leo: Ian Kunkler presented data from the PRIME-2 rand-
omized trial that included 1,326 patients aged 65 or older with 
hormone receptor-positive low-risk breast cancer. In  addition 
to endocrine treatment, the patients either received adjuvant 
radiotherapy (RT) or not. Although the investigators ob-
served a difference in 5-year ipsilateral breast tumor recur-
rence that favored RT, the absolute difference was small and 
overall survival did not differ between the groups. Interest-
ingly, patients whose tumors had high estrogen  receptor (ER) 
expression had a lower local recurrence rate than those with 
low ER expressing tumors when omitting RT. Especially for 
tumors with high ER expression, omission of RT in older 
 patients represents an option that can be  individually dis-
cussed with the patients. However, it is not a new standard, 
since the benefit of RT is still clearly shown. 
Aebi: The PRIME-2 trial (reported by Kunkler) is in line 
with prior North American trials [Hughes RT et al. J Clin 
Oncol 2013;31:2382–2387 and Fyles et al. N Engl J Med 
2004;351:963–970]. As such the superior local control by RT 
without any survival advantage is no surprise. This does not 
represent a new standard, as it merely confirms prior results; 
whether or not omission of whole breast irradiation is accept-
able depends on the weight given to local control by both 
 patients and their physicians.
Gnant: No. We have demonstrated in ABCSG-8a already 
several years ago that careful patient selection will result in a 
low locoregional relapse rate when RT is omitted after breast 
conservation – about 5%. However, as we have demonstrated 
in a randomized fashion, with RT these patients look at a 
0.5% risk – significantly lower. I still believe that leaving out 
RT should be reserved for rare situations of very frail patients 
or in the situation of severe comorbidity or transportation 
issues.
Harbeck: So far, there is no prospective data that radiation 
can be safely omitted. Yet, older patients with tumor charac-
teristics like the PRIME trial inclusion criteria need be in-
formed that the benefit may be reduction of local failure rate 
but not improving survival. There are also concepts of ‘less 
burdening’ RT such as hypofractionation or IORT alone 
which may present alternatives to full breast irradiation after 
breast conserving surgery in low-risk situations.
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Question 5: Beyond Estrogen Receptor, HER2,  
and Oncotype Dx – Do We Have New and More 
 Precise Techniques to Identify Patients Who  
Will Profit from Certain Therapies?
Aebi: Further to properties of the cancers, characteristics of 
the patients tend to be neglected. They should be just as much 
in the center of attention as cancer biology: concomitant dis-
eases and pharmacogenetic information might also in fluence 
the choice of therapy. Despite substantial advances in the bio-
logical understanding of breast cancers, no readily  applicable 
predictors have emerged that would facilitate the choice of 
therapies, be it in the adjuvant or in the advanced setting.
Gnant: Techniques to identify patients who will profit from 
certain therapies? Definitely. Tumor proliferation (measured 
e.g. by Ki67) is an important tool in my daily practice, based 
on high-quality conventional pathology. Also, Nanostring’s 
Prosigna® and Sividon’s Endopredict® habe demonstrated 
 excellent data, particularly for the issue of long-term risk (and 
thus may be useful for decision-making about extended adju-
vant therapy). 
Harbeck: Yes, definitely – we do have to get used to asking 
for more information about certain tumor types, in particular 
luminal ones before deciding about adjuvant chemotherapy 
for example. We presented the run-in phase of the WSG-
ADAPT trial at SABCS and were able to show feasibility of a 
short-term (3-week) induction endocrine therapy before sur-
gery in luminal tumors. Initial Oncotype DX as well as 3-week 
Ki-67 are then decisive for the chemotherapy decision. We 
expect to be able to spare about 50–60% of adjuvant chemo-
therapy in patients with 0–3 involved lymph nodes, in particu-
lar since in the intermediate-risk population, about 70% had a 
Ki-67 decrease < 10% after the 3-week endocrine therapy, 
 indicating sufficient response to endocrine therapy alone. 
Question 6: In Your Personal View, What Was  
the Most Relevant Finding at SABCS 2013? 
Aebi: The presentation of the first results of the I-SPY 2 
trial (Rugo) opens the field for a new generation of trial 
 designs allowing a more rapid identification of drugs with 
 potentially useful clinical activity. The statistical design 
is such that drugs selected by this procedure have a high 
probability of success in a randomized phase III trial; this 
may make the evaluation of the benefits of the numerous 
drugs in development more feasible than with traditional 
trial mechanisms.
Gnant: I probably have to admit to a personal bias: the 
final definition of the overall adjuvant bisphosphonate effect 
in postmenopausal women should finally settle these discus-
sions. Based on the meta-analysis of 22,000 patients, this is a 
major finding.
Harbeck: I personally think that the meta-analysis on 
 adjuvant bisphosphonates will have the greatest clinical im-
pact since it will be decisive for clinical practice as outlined 
before.
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